Immutep Receives Australian R&D Tax Incentive
SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2021 fiscal year, mainly related to the Company’s TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia.
- SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), is pleased to announce that it has received a A$986,286 (~US$659,303) cash rebate from the Australian Federal Governments R&D tax incentive program.
- Due to the Advance Finding, both Immuteps Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive.
- As previously announced, in September 2022, Immutep also received the French CIR tax incentive of 1,804,341 (~ US$1,862,143) through its subsidiary Immutep S.A.S in respect of expenditure incurred on eligible R&D activities conducted in the European Union during the 2021 calendar year.
- Immutep will apply the non-dilutive funding towards furthering its current active clinical trial programs for its lead product candidate, efti.